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Abstract
Alpha-dystroglycan (a-DG) is a ubiquitously expressed receptor for extracellular matrix proteins and some viruses, and plays
a pivotal role in a number of pathological events, including cancer progression, muscular dystrophies, and viral infection.
The O-glycans on a-DG are essential for its ligand binding, but the biosynthesis of the functional O-glycans remains obscure.
The fact that transient overexpression of LARGE, a putative glycosyltransferase, up-regulates the functional glycans on a-DG
to mediate its ligand binding implied that overexpression of LARGE may be a novel strategy to treat disorders with
hypoglycosylation of a-DG. In this study, we focus on the effects of stable overexpression of Large on a-DG glycosylation in
Chinese hamster ovary (CHO) cell and its glycosylation deficient mutants. Surprisingly, stable overexpression of Large in an
O-mannosylation null deficient Lec15.2 CHO cells failed to induce the functional glycans on a-DG. Introducing the wild-type
DPM2 cDNA, the deficient gene in the Lec15.2 cells, fully restored the Large-induced functional glycosylation, suggesting
that Large induces the functional glycans in a DPM2/O-mannosylation dependent manner. Furthermore, stable
overexpression of Large can effectively induce functional glycans on N-linked glycans in the Lec8 cells and ldlD cells
growing in Gal deficient media, in both of which circumstances galactosylation are deficient. In addition, supplement of Gal
to the ldlD cell culture media significantly reduces the amount of functional glycans induced by Large, suggested that
galactosylation suppresses Large to induce the functional glycans. Thus our results revealed a mechanism by which Large
competes with galactosyltransferase to target GlcNAc terminals to induce the functional glycans on a-DG.
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Introduction
Alpha-dystroglycan (a-DG), a highly glycosylated plasma
membrane-associated protein, was originally isolated from brain
and skeletal muscle [1,2]. It is encoded by DAG1 gene and
expressed ubiquitously [3]. The DAG1 gene is translated as a single
polypeptide which is post-translationally cleaved into two subunits:
a-DG and b-DG. The two subunits associate non-covalently as the
key components of the dystrophin glycoprotein complex (DGC)
[4]. Alpha-DG associates with extracellular matrix (ECM)
proteins, while the transmembrane b-DG interacts with the sub-
membrane dystrophin or utrophin, which is, in turn, linked to
actin-based cytoskeleton. Proper glycosylation of a-DG is essential
for its binding to the ECM proteins such as agrin, laminins,
neurexin, and perlecan. The linkage between ECM and the
cytoskeleton through DGC is critical for the membrane integrity
and functions of skeletal muscles. Alpha-DG consists of three
distinctive domains, an N-terminal globular domain, a central
mucin domain, and a C-terminal globular domain. The mucin
domain (317–488aa) has a cluster of 50 Ser/Thr residues, which
are potential sites for O-glycosylation. Removing the O-glycans on
a-DG abolishes its ligand binding, indicating that the O-glycans
are essential for the activity [4], although the exact structure of the
O-glycans mediating its ligand binding remains largely unknown.
The importance of the O-glycans on a-DG has been illustrated by
the discoveries that the mutations in known and putative glycosyl-
transferase genes such as POMT1/2, POMGnT1, LARGE, Fukutin,
and Fukutin-related protein (FKRP) cause aberrant O-glycosylation of
a-DG and result in various muscular dystrophies with a wide
spectrum of clinical manifestations (termed as dystroglycanopa-
thies) [5,6,7,8,9,10]. The hallmark of these diseases is the
hypoglycosylation of a-DG and reduced binding of the a-DG to
laminin. However, among these genes, only POMT1/2 and
POMGnT1 have been demonstrated to have the glycosyltrans-
ferase activities in the protein O-mannosylation pathway [6,11].
The roles of LARGE, Fukutin, and FKRP in glycosylation of a-
DG remain to be defined.
Human LARGE was originally identified as a tumor related
gene with deletion in meningioma [12]. It is a type II
transmembrane glycoprotein with 756 amino acids, residing
predominantly in the Golgi apparatus [13]. Its N-terminal and
C-terminal domains have sequence similarities to bacterial a-
glycosyltransferase and mammalian b-1,3-N-acetylglucosaminyl-
transferase, respectively. Despite the fact that glycosyltransferase
activity of the LARGE gene has not been demonstrated,
accumulating evidence suggested that LARGE plays a critical
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be detected by immuno-staining with the IIH6 and VIA4
monoclonal antibodies and laminin binding assays. Significantly,
aberrant glycosylation of a-DG is frequently associated with a
variety of tumors, which have LARGE expression silenced
[14,15,16,17]. Interestingly, Campbell and colleagues reported
that transient overexpression of LARGE can functionally bypass
distinct genetic defects in myoblasts derived from patients with
mutations in FCMD, POMT1, and POMTGnT1 [18]. Furthermore,
previous studies also reported that transient expression of LARGE
induced abundant functional glycans in the B421 and Lec15.2
cells with O-mannosylation defects, suggesting that transient
overexpressing LARGE may process non O-mannosyl glycans to
induce the functional glycans on a-DG [19,20,21,22]. However,
whether Large-induced functional glycosylation of a-DG is O-
mannosylation dependent in physiological conditions remains
unknown. Overexpressing LARGE can bypass hypoglycosylation
of a-DG caused by non LARGE defects, suggested that
overexpression of LARGE could be a potential therapeutic
strategy for patients with hypoglycosylation of a-DG. However
the detailed mechanism by which LARGE induces the functional
glycans remains to be elucidated.
In the present study, we have utilized CHO cells and its
glycosylation deficient mutants: Lec1, Lec2, Lec8, Lec15, and ldlD
cells [23] and established an array of the cell lines with stable
overexpression of mouse Large. With the O-mannosylation null
deficient Lec15.2 cells, we demonstrated that stable overexpression
of Large induces the functional glycans in a dolichol phosphate-
mannose biosynthesis regulatory protein 2 (DPM2)/O-mannosy-
lation dependent manner, thus confirming for the first time that
Large is involved in modification of O-mannosyl glycans on a-DG.
Quantitative analysis of the glycans on a-DG in the Lec8 and ldlD
cells expressing Large revealed that Large can effectively induce
the functional glycans on N-linked glycans. In addition, supple-
ment of Gal to the conditioned media of ldlD-Large cell culture
significantly reduced the amount of functional glycans, suggesting
that galactosylation suppresses Large to generate the functional
glycans. Our results revealed a mechanism by which Large
competes with galactosytransferases to target GlcNAc terminals to
generate the functional glycans on a-DG.
Results
Stable overexpression of Large induces the functional
glycans independent of Gal, sialic acids, and complex
N-linked glycans
Previous reports on Large function were all carried out with
transient overexpression, which often have extremely high but
unsustainable levels of Large expression [19,20,21,22]. To
investigate the effect of stable overexpression of Large on specific
glycans, we have established an array of glycosylation deficient
CHO cell lines (Pro5, Lec1, Lec2, and Lec8), in which mouse
Large tagged with a MYC epitope was stably expressed and
termed as Pro5-LG, Lec1-LG, Lec2-LG, and Lec8-LG, respec-
tively. The Lec2 and Lec8 cells are deficient in the Golgi CMP-
sialic acid transporter and UDP-Gal transporter, respectively [23].
Consistent with previous reports with transient Large overexpres-
sion, stable overexpression of Large in both cells induced
abundant functional glycans on a-DG as determined by the
IIH6 monoclonal antibody, which recognizes the epitope(s)
overlapping with laminin binding glycans on a-DG. Glycans on
a-DG recognized by both the antibodies and laminin binding
assay have been widely referred to as the functional glycans [24].
Similarly, the functional glycans were produced abundantly in the
Lec1-LG cells deficient in enzyme MgalT1, which is essential for
complex N-glycan formation on proteins [23]. The biological
functions of the Large-induced functional glycans on a-DG in
these cells were further supported by their cell surface localization
examined by immuno-fluorescent microscopy with the IIH6
antibody (Fig. 1B) and the laminin cluster assay (Fig. 1C). These
results are consistent with previous observation using transient
expression methodology (Fig. 1, 2), suggested that stable
overexpression of Large induced the functional glycans indepen-
dent to Gal, sialic acids, and complex N-linked glycans.
Stable overexpression of Large induces the functional
glycans in a DPM2 dependent manner
Large has been thought to modify O-mannosyl glycans to
produce the functional glycans on a-DG to mediate its ligand
binding. However, so far there has been no direct experimental
evidence to support the hypothesis. To investigate the role of
Large in o-mannosylation of a-DG, we established a stable cell line
with Lec15.2 cells, in which Large was stably expressed. The
Lec15.2 cell is deficient in DPM2 that plays an essential role in the
complex of DPMs to produce dolichol-phosphate-mannose (Dol-
P-Man). The Dol-P-Man is the substrate for enzymatic complex of
POMT1/2 to initiate O-mannosylation of a-DG by adding the
first mannose to Ser/Thr residues of a-DG in the lumen of ER
[11]. Surprisingly, stable overexpression of Large failed to induce
significant amount of the functional glycans in the Lec15.2 cells.
The amount of the functional glycans was undetectable in the
lysates from the Lec15.2-LG cells with the IIH6 antibodies, while
its Large expression level is compatible to that in the other CHO-
LG cell lines (Fig. 1A). The lack of the functional glycans on the
Lec15.2-LG cells was further confirmed by the immuno-staining
and laminin clustering assay (Fig. 1B, C). The results are
apparently in contradiction to the previous reports in which
several groups showed that transient overexpression of Large
induced abundant functional glycans in either the B421 or LG
15.2 cells which are both deficient in the DPM2 gene
[19,20,21,22]. The Lec15.2-LG cells used in this study were
selected from a large population of Lec15.2 cells. One possibility is
that the selected Lec15.2-LG clones might have acquired
additional genetic defects which may compromise the activity of
Large. To address this issue, we independently repeated Large
transfection of the Lec15.2 cells (3 times) and screened 1,000
clones overexpressing Large by indirect immuno-fluorescent
microscopy. About 10% of transferant cells were capable of
producing detectable IIH6 reactive glycans on the cell surface
within 4-6 weeks after transfection. However, majority of the
Lec15.2-LG clones gradually lost the capacity to induce the
function glycans after 20 passages in continuing cell culture for 4
months (Fig. 2) despite the fact that the levels of Large expression
are compatible to that in other tested CHO-LG cell lines (Fig.1
and 2). Four Lec15.2-LG clones retained the capacity of inducing
functional glycans, but at much lower levels when compared to the
other CHO-LG cells including Lec2-LG, Lec8-LG, and B421-LG
cells. Three of the 4 IIH6 positive clones (Lec15.2-LG) were
further examined by Western blotting for the amount of functional
glycans and levels of Large expression together with Pro5-LG,
B421-LG, and negative controls (Fig. 2). For comparison, the
B421 cells were also transfected with the same Large expression
construct and a number of clones were selected. In contrast to the
Lec15.2-LG clones, all the B421-LG clones stably overexpressing
Large maintained production of abundant functional glycans after
4 months culture (the same period for Lec15.2 clones), although
the amount of functional glycans were about 50% of that in Pro5-
LG cells (Fig. 2). The expression levels of Large in these B421-LG
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Lec15.2-LG clones by the Western blotting assay. The consistent
results between independent Large transfection experiments
suggested that additional genetic defects are unlikely the reason
responsible for loss of Large activity in the Lec15.2 cells.
To further address whether the deficiency of DPM2 is
responsible for the loss of the Large function in the Lec15.2 cells,
we conducted complementation experiments by introducing a
wild-type mouse DPM2 cDNA into the Lec15.2-LG cells. In the
experiments, the Lec15.2-LG cells were transfected with the
DPM2 mammalian expression construct, and then examined by
Western blot and laminin overlay assays (Fig. 3A). The DPM2
transfection restored Large function in the Lec15.2-LG cells, while
DPM2 expression alone did not produce detectable the functional
glycans. Furthermore, we also overexpressed DPM2-GFP in the
Lec15.2-LG cells and examined functional glycans on the cell
surface. Indeed, the expression of DPM2-GFP restored the Large
function to produce the functional glycans in the Lec15.2-LG cells,
while expression of DPM2-GFP alone failed to do so in either the
Lec15.2 or the Pro5 cells (Fig. 3B). The results suggested that
stable overexpression of Large induces the functional O-glycans on
a-DG to mediate laminin binding in a DPM2/O-mannosylation
dependent manner.
Stable overexpression of Large can effectively modify
N-linked glycans in the absence of galactosylation
It has been reported that transient overexpression of Large
modifies complex N-glycans on a-DG, particularly, in the Lec8
cells [19]. To investigate whether stable overexpression of Large
has effect on N-linked glycans of a-DG as well, we used PNGase F
to remove the N-linked glycans on a-DG from the Pro5-LG,
B421-LG, Lec15.2-LG, Lec8-LG and ldlD-LG cells growing in
the complete media (Fig. 4). The reduction of IIH6 staining signal
in Pro5-LG, B421-LG, and Lec8-LG represents the amount of
functional glycans on N-linked glycans and the remaining
functional glycans would be on O-glycans. In the Lec15.2-LG
cells, the remaining functional O-glycans would be on mucin type
of O-glycans only since the cells are lack of O-mannosyl glycans
due to missing DPM2 activity. Interestingly, removing N-linked
glycans did not reduce significant amount of functional glycans on
Figure 1. Stable overexpressing Large induces functional
glycans in CHO cells. (A) Equal amount of lysates (60 mg proteins
each lane) extracted from the cells stably expressing Large as indicated.
The immuno-blotting procedure was described in methods section. The
glycan antibody IIH6 and anti-MYC antibody (9E10) were used to detect
the functional glycans and Large–MYC, respectively. In addition, an anti-
b-DG (MANDAG2) antibody was used for detecting dystroglycan as the
loading control. (B) The cells as indicated were seeded in 96-well plates
and immuno-fluorescent staining was performed as described in the
methods section. The images in top panel present the negative
controls, while the images of bottom panel present the Large positive
cells. A rabbit polyclonal anti-MYC antibody and the IIH6 antibody were
used to stain the Large-MYC and glycosylated a-DG, respectively. The
cells were also stained with DAPI to visualize the nucleus. The bar is
50 mm. (C) The cells as indicated were seeded in 96-well plate for
24 hour growth. The protocol of laminin clustering assay is described in
the methods section. The laminins-DyLight488 was added to the cell
culture for 6 hours incubation. A rabbit polyclonal anti-MYC antibody
was used to stain Large-MYC protein followed by staining with
secondary anti-rabbit antibodies conjugated with Alex594. In addition,
DAPI was added to each well to stain the DNA for cells counting. The
images were captured with a fluorescent microscope as described in
methods section. The bar is 50 mm.
doi:10.1371/journal.pone.0016866.g001
Figure 2. Stable overexpression levels of Large on glycosyla-
tion of a-DG in the Lec15 cells. Pro-5, B421 clones overexpressing
(+) or without (2) Large-MYC or Lec15.2 cells overexpressing Large-MYC
at high +(H), modest +(M) low +(L) or without Large-MYC (2) were
tested by immuno-blot assay. The blot of the Lec15.2 samples had 10
mins exposure, while all other blot had about 10 seconds’ exposure
time.
doi:10.1371/journal.pone.0016866.g002
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remaining functional glycans after PNGase F digestion was
reduced to about 50% of that of untreated samples from Lec8-
LG cells, suggesting that stable overexpression of Large only
modifies N-linked glycans on a-DG to induce the functional
glycans effectively in the galactosylation deficient Lec8 cells.
GalNAc enhances, whereas Gal and Gal/GalNAc inhibit
production of Large-induced functional glycans in ldlD-
LG cells
The structure of Large-induced functional glycan is unknown;
and there is no method available to selectively remove O-
mannosyl or mucin-type of O-glycans. Thus it is difficult to study
the effects of Large on O-mannosyl and mucin-type O-glycans,
separately. To circumvent this hurdle, we took advantage of the
reversible glycosylation deficient CHO cells, ldlD cells, which are
deficient in UDP-galactose 49-epimersase (GALE) and produce
neither UDP-GalNAc nor UDP-Gal resulting in pleiotropic
glycosylation pathway defects [25]. Supplement of GalNAc and
Gal to the cell culture media can restore the glycosylation
pathways due to a salvage pathway in the CHO cells (Fig. 5A)
[25]. Thus the mucin-type O-glycan biosynthesis could be
manipulated by supplementing the sugar(s) to the cell culture
media. In the experiments, the stable ldlD-LG cells were grown in
the media with 3% lipoprotein deficient serum for 48 hours to
deplete the intracellular UDP-GalNAc and UDP-Gal pools [25].
Under this culture condition the ldlD cells do not produce
detectable mucin-type O-glycans by radioisotope labeling meth-
odology [25]. We examined the amount of the functional glycans
produced in the ldlD-LG cells growing in the cell culture media
with different sugar supplements. Strikingly, the ldlD-LG cells
produced the least amount functional glycans when grown in the
medium supplement with both Gal and GalNAc, despite the
glycosylation pathways were restored and evidenced by the b-DG
immuno-blotting (Fig. 5). In contrast, the cells produced the most
abundant functional glycans when supplemented with GalNAc
alone. The comparison of the amount of the functional glycans
produced in the ldlD-LG cells growing in different culture media
[GalNAc (2.4) . non sugars (1.8). Gal (1.6).GalNAc and Gal
(1)] is shown in Fig. 5B,C. To further analyze the effects of Large
on N-linked and O-linked glycans quantitatively in the ldlD-LG
cells, we removed the N-glycans from the a-DG proteins with
PNGase F, which were harvested from the conditioned culture
media with or without GalNAc (Fig. 5D, E). The results showed
that without supplement of Gal and GalNAc, ,35% of the Large-
induced functional glycans were on N-linked glycans (digested
portion) and ,65% were on O-mannosyl glycans (remaining
portion), since the mucin-type of the O-linked glycans are
expected to be minimal. Supplement of GalNAc alone increases
the total functional glycans by about ,28% comparing with that
in the no sugar addition and about 25% of the functional glycans
are on N-linked glycans (Fig. 5D,E).
Discussion
In this study, we demonstrated that Large, a putative
glycosyltransferase, induces the functional glycans on a-DG to
mediate laminin binding in a DPM2/O-mannosylation dependent
Figure 3. Overexpressing DPM2 restores the Large function in
the Lec15.2 cells. (A) Transient transfection was conducted to
introduce mouse DPM2 cDNA into the Lec 15.2-LG cells. 48 hours after
transfection, the cell lysates were harvested and immuno-blotting assay
and laminins overlay assay were conducted as described above. (B) A
transient transfection was conducted to introduce DPM-GFP cDNA into
the cells in 96-well plate. 48 hours the after transfection, cells were fixed
and an indirect immuno-fluorescent staining with IIH6 antibody was
conducted with the protocol as described in the methods section. The
images were captured with a fluorescent microscope as described in
methods section. The bar is 50 mm.
doi:10.1371/journal.pone.0016866.g003
Figure 4. Effects of Large-induced pathway on N-linked
glycans. (A) All cells were grown in the completed media as described
in the methods section and the lysates harvested from the indicated
cells with stably expressing LARGE were treated with pNGase F for
4 hours, while it is absent in the negative controls reactions as
described in the methods section. IIH6 antibody was used to determine
the LARGE induced glycans, and the anti-b-DG antibody was used to
determine the b-DG proteins as described above. The blot of the
Lec15.2 samples with the IIH6 antibody had 30 mins exposure, while all
other blots had about 10 seconds’ exposure time.
doi:10.1371/journal.pone.0016866.g004
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glycosylation on a-DG, but it can be restored by expressing DPM2
in the Lec15.2-LG cells. Thus our results confirmed for the first
time that Large is involved in the biosynthesis of the O-mannosyl
glycans suggested by the results from clinical and mouse genetic
studies. This result is also in-line with the recent report that the
functional glycans may be linked to the first mannosyl residue of
the O-mannosyl glycans on mucin domain [26]. It was curious to
learn that the discrepancy between the results of the effects of
stable expressing Large on a-DG glycosylation in the two Lec15
clones, B421 and LG15.2 cells. It can be explained that the B421
cells harbor the point mutation form of DPM2 which may allow
the cells to produce sufficient amount of Dol-P-Man to support the
function of stable expressing Large to produce abundant
functional glycans. But the Lec15.2 cells produce neither DPM2
message RNA nor Dol-P-Man that is essential substrate for
POMT1/2 complex to initiate the biosynthesis of O-mannosyl
glycans in the ER lumen, thus resulting in loss of the Large activity
in the Lec15.2 cells. On the other hand, when transient
overexpression at extremely high level Large can produce the
functional glycosylation of a-DG in the Lec15.2 cells (data not
shown), suggested that Large can induce the functional glycans on
N-linked and mucin O-glycans to bypass defects in the early steps
of O-mannosylation pathway. But it can not be sustained.
Our results obtained from the sugar addition experiments with
ldlD-LG cells clearly suggested that Gal inhibits the ability of
Large to induce the functional glycans on the N-linked and mucin-
type O-glycans. The mucin-type O-glycans consist of four
components: Sia, Gal, GlcNAc, and GalNAc. Sia, Gal, and
GalNAc are not the essential components of the functional glycans
and addition of Gal or both Gal and GalNAc together even
inhibited the functional glycosylation induced by Large. Thus only
the GlcNAc could be the Large’s target on mucin-type of O-
glycans. This also explains that Large induces the functional
Figure 5. LARGE modifies both mucin type O-glycans and N-linked glycans on a-DG in ldlD cells while without galactosylation.
(A) Predicted structures of the glycans in N-linked, Mucin and O-mannosyl pathway in the ldlD cells. (B)The ldlD-LG cells were maintained in F12
nutrition mix media with 3% lipoprotein deficient bovine serum for more than 48 hours prior to the experiment. The cells were seeded into 6-well
plates one day before addition of indicated sugars (Gal at 10 mM and GalNAc at 200 mM). After being treated with the sugar(s) for 24 hour, the cell
lysates were harvested and equal amount of the lysates were loaded. An immuno-blotting assay was performed to detect the functional glycans and
b-DG with the IIH6 and b-DG antibody, respectively. (C) The quantitative data of the expression levels of the functional glycans were obtained with
AlphaImage AIC software based on densitometers followed the manufacture instructions. The IIH6 expression levels were normalized with the
expression levels of b-DG (N=3). (D) The lysates harvested from the ldlD-LG cells growing in the conditions as indicated and the experimental
procedure is the same as described in (Fig. 4A). (E) Quantitative analysis of the data of (D) (N=3).
doi:10.1371/journal.pone.0016866.g005
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cells (Lec8) since the GlcNAc terminals are enriched on the N-
glycans in galactosylation defective condition. Our results
suggested that Large-pathway targets GlcNAc terminals to
generate the functional glycans in various glycans. A recent study
also suggested that b-1,3-N-acetylglucosaminyl-transferase is
essential for functional glycosylation of a-DG in a prostate cancer
cell line, supporting the view that GlcNAc terminals may be the
target of Large-pathway[22].
Surprisingly, addition of GalNAc alone to the conditioned
media of ldlD-LG cell culture remarkably enhances the Large-
induced functional glycans on a-DG. In contrast, addition of both
Gal and GalNAc to the ldlD-LG cell culture media resulted in
producing much less functional glycans in the cells despite all
glycosylation pathways are supposed to be restored in this
condition. The phenomenon may be explained as follow. When
the ldlD cells grown in the media without Gal/GalNAc, Large-
pathway targets the GlcNAc terminals on O-linked and N-linked
glycans to produce abundant functional glycans. Supplement of
Gal alone to the culture media allows the cells to add Gal to the
GlcNAc terminals on O- and N-linked glycans and results in
inhibiting Large-pathway to target GlcNAc terminals to generate
the functional glycans. While supplement of GalNAc alone to the
cell culture the ldlD-LG cells add more GalNAc to the abundant
Ser/Thr (up to 50) residues on the mucin domain to initiate the
biosynthesis of mucin O-glycans. Sequentially, the GalNAc
residues would be modified by endogenous bGlcNAc-transferases
(bGn-Ts) to produce more GlcNAc terminals, since Gal is not
available. Thus, Large modifies the abundant GlcNAc terminals to
produce the most amount of the functional glycans among the cell
culture conditions. Finally, while supplement of both Gal and
GalNAc to the cell culture media, bGal-transferases (bGal-Ts)
would modify GlcNAc terminals on all types of glycans, thus
preventing Large to modify GlcNAc terminals to produced the
functional glycans. Our data also suggested that fully restoration of
mucin type of O-glycosylation with supplement of both Gal and
GalNAc may compete with the functional O-mannosylation
induced by Large. This is supported by recent report that the
O-GalNAcylation and O-Mannosylation pathways are competing
for the same sites of modification on a-DG[27]. Thus Large
produced the least amount of the functional glycans among the cell
culture conditions (Fig.5). The difference between the functional
glycans biosynthesis in the different glycosylation conditions is
unlikely due to protein degradation or other nonspecific effects
caused by glycosylation defects. Since the functional glycans
biosynthesis is suppressed in the better glycosylation conditions
rather than in the worse conditions (Fig. 5).
To date, four O-glycans structures on a-DG have been
reported: NeuAca2-3Galb1-4GlcNAcb1-2Man (the tetra-glycan)
from bovine brain and rabbit skeleton muscles [28,29]. Galb1-
4(Fuca1-3)GlcNAcb1-2Man (Lewis
X structure) from sheep brain
[30], HSO3-3GlcAb1-4GlcNAcb1-2Man (HNK1 epitope) from
rat brain [31,32], and Galb1-3GalNAc (Core-1) from myotubes
[33]. The diversity of the O-glycan structures on a-DG allows a-
DG to play distinct roles in various tissues to mediate the
interactions with its variety of ligands. For example, HNK-1
epitope containing O-glycan mediates a-DG binding to laminins
10/11 in brain [32], while its core-1 structure of mucin-type
glycan on a-DG mediates laminin-induced acetylcholine receptor
clustering but not laminin binding activity in myotubes [33]. Our
results suggested that the NeuAca2-3Galb1-4GlcNAcb1-2Man
glycan can not be the Large-induced functional glycans mediating
laminin binding. Considering the N- and C-terminal domains of
LARGE is related to bacterial a-glycosyltransferase and b-1,3-N-
acetylglucosaminyl-transferase, respectively. In addition, Large
itself is able to bind to a-DG. It is likely that Large function as
glycosyltransferase modifying the GlcNAc to generate the
functional glycans. Although the structure of Large-induced
functional glycan remains to be determined, Our results
nevertheless provided insights into the glycosylation of a-DG,
which are illustrated in the Fig.6. 1) Large predominantly modifies
O-mannosyl glycans to produce the functional glycans at stable
overexpression levels in CHO cells, implicating that so does the
endogenous Large. 2) Over expression of Large competes to
modify GlcNAc terminals with galactosylation to generate the
functional glycans on both O-linked and N-glycans, suggesting
that suppressing galactosylation to produce more GlcNAc
terminals on a-DG would significantly enhance Large function
to produce the functional glycans, which may be a potential way to
enhance the biosynthesis of the functional glycans on a-DG.
Materials and Methods
Antibodies and Laminins
Mouse anti-glycosylated a-DG mAb IIH6 (Upstate Biotechnology,
Inc.) was used at 1:200 and 1:1000 dilutions for Immuno-fluorescent
staining and Immuno-blotting assay, respectively. Anti-b-DG MAb
43DAG1/8D5 (hybridoma conditioned medium) from DHSB was
used at 1:200 dilution. Mouse anti-MYC mAb 9E10 (DHSB) was
used at 1:500 dilution. Rabbit anti-GM130 antibody (Stressgen) was
used at 1:500 dilution. Rabbit anti-laminin-1 polyclonal antibody
(Sigma) was used at 1:400 and 1:1500 dilution for Immuno-
fluorescent staining and immuno-blotting assay, respectively. Anti-
GFP mAb (JL-8) (Clontech) was used at 1:100 for immuno-
precipitation and 1:5000 for immuno-blotting assay. Laminins
(laminin from Engelbreth-Holm-Swarm murine sarcoma basement
membrane, Sigma) was used at dilution 5 mg/ml for laminins overlay
assay. Horseradish peroxidase-conjugated anti-mouse, anti-rabbit,
and anti goat secondary antibodies (Sigma) were used at 1:5000–
1:10,000 dilutions. Alexa-488, 594 conjugated secondary antibodies
(Invitrogen) were used at 1:200–1:500 dilutions.
Expression Constructs
The mouse LARGE construct in pcDNA3.1/Myc-His(-)B
vector was provided by Pamela Stanley [19]. Mouse DPM2
constructs in pCMV-Kan/Neo vector with or without GFP tag
were purchased from Origene. The construct for human a-
dystroglycan tagged with human Ig FC-fragment (HIG) was
generated by cloning the a-DG cDNA fragment into the Pfuse-
higG1-Fc vector (Invivogen). All constructs were confirmed by
sequencing in Carolinas Medical Center molecular biology facility.
Cell Culture, Transfection, and Stable Cell Lines
Pro5 and the glycosylation-deficient CHO mutants termed Lec1,
Lec2,and Lec8 were purchasedfrom ATCC [23].TheLec15.2and
B421 cell lines were kindly provided by Mark Lehrman and Sharon
Krag, respectively [34,35]. These CHO cells were grown and
maintained inF12nutritionmixmediawith10%fetalbovineserum
(Invitrogen) in plates with 5% CO2 at 37uC, except that the Lec15
cells were grown at 34uC. For transfection, the cells were seeded in
6-wellsplates, andweretransfectedusing Fugene 6 reagents (Roche)
followed the manufacturer’s guidelines. For selecting stable cell lines
expressing LARGE-MYC, the cells were cultured with G418 at
1.2 mg/ml (Invitrogen) 48 hours after transfection. The clones
resistant to G418 were screened with laminin-dylight488. The
positive clones binding to laminin-Dylight488 were picked and
further confirmed with immuno-fluorescent staining with an anti-
MYC monoclonal antibody.
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Cell lysates were prepared from stable cell lines or transient
transfectants 2 days after transfection. For each 10 cm plate, 1 ml
of lysis buffer (1.5% Triton X-100 in PBS with protease inhibitor
cocktail from ROCHE) was used to harvest the cells. The
concentration of proteins in lysates was determined by Bio-Rad Dc
protein assay. For electrophoresis, lysates (60 mg of protein) were
boiled for 5 min in SDS-PAGE gels loading buffer. After
electrophoresis in 4–12% gradient polyacrylamide gels (Invitrogen)
at 168 V for 90–120 min, proteins were transferred to poly-
vinylidene difluoride membrane for 3 hours at 200 mA in transfer
buffer containing 10% methanol. For immunoblotting, mem-
branes were blocked in PBS with 10% fat free milk and incubated
in the same solution with primary antibody at room temperature
for 1 hour. After washing in PBS for 5X5 min, membrane was
incubated in PBS/milk with horseradish peroxidase-conjugated
secondary antibody for 1 hour at room temperature. After
washing in PBS for 5X5 min, membrane was incubated in Super
Signal West Pico
TM chemiluminescence reagent (Pierce) and
exposed to photographic film (Eastman Kodak Co.).
Laminin Binding Assay with Cells
The cells were seeded in 96 well plates for overnight incubation.
Then the cells were fixed and permeablized in 0.2% Triton X-100
in the laminin overlay buffer (LBB, 10 mM ethanolamine,
140 mM NaCl, 1 mM MgCl2 and 1 mM CaCl2, pH 7.4) for
8 min and blocked with 10% BSA for 1 hour at 37uC. Then 50 ml
of 5 mg/ml laminins-DyLight-488 labeled in the LLB was
incubated with the cells for 2 hours at 37uC. The plates were
washed for 6 times with a micro-plate washer (BioTeck EXL405)
and read with Infinite 500 microplate reader (TECAN). For
staining the LARGE-MYC, an immuno-staining experiment was
conducted with the anti-MYC polyclonal antibody.
Laminin Clustering Assay
The cells were seeded in 96 well plates for overnight incubation.
Then the cells were incubated with 50 mlo f5mg/ml laminins-
DyLight-488 labeled in LBB for 6 hours at 37uC in cell culture
incubator. The cells were washed with LLB twice and fixed. The
cells were washed twice again and 50 ml LLB per well were added,
and plates will be ready for microplate reading or capturing
images with fluorescent microscopy.
Laminin Overlay Assay
The cell lysates were separated by SDS-PAGE gels and
transfered to Nitrocellulose membranes. The membranes were
blocked in 10% non-fat milk in LLB for 1 hour, and then
incubated with 2.5 mg/ml laminin at 4uC overnight. After washing
with LLB 5x5 min the laminin binding to a-DG was detected by
standard Immunoblotting as describe above with a laminin
polyclonal antibody (Sigma) followed by a goat anti-mouse IgG-
HRP secondary antibody.
Figure 6. Illustration of the role of Large in the glycosylation of a-DG. LGIFG: Large-induced functional glycans.
doi:10.1371/journal.pone.0016866.g006
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The cells were fixed, permeablized, and then blocked with 10%
BSA in PBS for 1 hour. The primary antibodies in PBS with 10%
BSA were incubated with the cells for 1 hour at room temperature
(22uC) followed by addition of secondary antibodies conjugated
with Alexa-488/594. After washing the cells with PBS for 2 times,
the DAPI was used to stain the cells for 15 mins and wash 3 times
with PBS. The images were captured with an inverted Olympus
fluorescent microscope.
PNGase F digestion
The deglycosylation procedure was followed the instruction by
manufacture (NEB, Ipswich, MA). 50 mg of total protein extracted
from indicated cells were boiled for 10 min in 1x Glycoprotein
Denaturing Buffer followed by incubation with 500 units of
PNGase F at 37uC for 4 hours. Samples were analyzed by
immuno-blotting assay as described above.
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